Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Accumulated Depreciation (2018 - 2024)

Bicycle Therapeutics (BCYC) has disclosed Accumulated Depreciation for 7 consecutive years, with $16.6 million as the latest value for Q2 2024.

  • For Q2 2024, Accumulated Depreciation rose 59.03% year-over-year to $16.6 million; the TTM value through Jun 2024 reached $16.6 million, up 59.03%, while the annual FY2023 figure was $13.4 million, 70.33% up from the prior year.
  • Accumulated Depreciation hit $16.6 million in Q2 2024 for Bicycle Therapeutics, up from $14.9 million in the prior quarter.
  • Across five years, Accumulated Depreciation topped out at $16.6 million in Q2 2024 and bottomed at $2.8 million in Q1 2020.
  • Average Accumulated Depreciation over 5 years is $7.3 million, with a median of $5.1 million recorded in 2022.
  • Year-over-year, Accumulated Depreciation increased 15.09% in 2022 and then skyrocketed 101.58% in 2023.
  • Bicycle Therapeutics' Accumulated Depreciation stood at $4.0 million in 2020, then grew by 19.05% to $4.8 million in 2021, then skyrocketed by 63.81% to $7.9 million in 2022, then surged by 70.33% to $13.4 million in 2023, then rose by 23.99% to $16.6 million in 2024.
  • According to Business Quant data, Accumulated Depreciation over the past three periods came in at $16.6 million, $14.9 million, and $13.4 million for Q2 2024, Q1 2024, and Q4 2023 respectively.